What are the upcoming clinical trials or regulatory decisions that could impact ABBV's stock price?

AbbVie (ABBV) has several upcoming clinical trials and regulatory decisions that could impact its stock price. Here are some key events to watch: 1. **IMGN151 Study**: AbbVie's Phase 1b study of IMGN151 in gynecologic cancers is a potential game-changer, as it explores new treatment combinations that could improve outcomes for patients. The study's success could enhance AbbVie's position in the oncology market and boost investor confidence. 2. **CLL Treatment Study**: The prospective, open-label, Phase IIb/III study on venetoclax in combination with obinutuzumab or acalabrutinib for CLL is another significant event. This study could significantly impact AbbVie's market position by potentially enhancing its CLL treatment portfolio. 3. **ABBV-951 FDA Review**: The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for ABBV-951, which AbbVie is working to resolve as quickly as possible. A favorable outcome could expand access to this treatment for patients with advanced Parkinson's disease. 4. **Pipeline Developments**: AbbVie continues to support early R&D efforts at Calico and has the option to manage late-stage development and commercial activities following Phase 2a studies. This could lead to new product launches and revenue streams. These events are likely to influence investor sentiment and could lead to fluctuations in AbbVie's stock price. Successful outcomes from these trials and regulatory decisions could positively impact the stock, while adverse results or delays could lead to negative pressure.